Jan 17, 2024
Featuring perspectives from Dr Richard M Stone, including the
following topics:
• Introduction: ASH 2023 Update — Key Oral Presentations
(0:00)
• Case: A woman in her early 90s with dementia who presented
with anemia and was diagnosed with low-risk myelodysplastic
syndromes (MDS) with ring sideroblasts, now receiving luspatercept
— Eric H Lee, MD, PhD (9:09)
• Case: An African American woman in her early 60s with
high-risk del(5q) MDS who receives oral decitabine/cedazuridine —
Henna Malik, MD (26:05)
• Case: A man in his late 60s with therapy-related acute
myeloid leukemia (AML) with a FLT3-ITD mutation — Rebecca L Olin,
MD, MSCE (34:49)
• Case: A woman in her early 70s with PMH of inflammatory
breast cancer diagnosed with FLT3-ITD AML who achieved a complete
response (CR) with azacitidine/venetoclax, followed by gilteritinib
maintenance for 2 years — Zanetta S Lamar, MD (40:43)
• Case: A man in his mid 30s who presents with pathologic
spinal fracture, is diagnosed with myeloid sarcoma and receives
induction CLAG-M with CR followed by consolidation high-dose
cytarabine — Anna Halpern, MD (43:56)
• Case: A man in his mid 80s with MDS, complex cytogenetics
and a TP53 mutation treated with azacitidine/venetoclax — Neil
Morganstein, MD (46:40)
• Case: A woman in her early 70s with newly diagnosed,
poor-risk AML, ineligible for intensive chemotherapy (ECOG PS 2)
who receives a hypomethylating agent/venetoclax — Amany R
Keruakous, MD, MS (49:56)
• Case: A man in his early 70s with relapsed AML (SRSF2, IDH1,
ASXL1 mutations) after azacitidine/venetoclax, now receiving
ivosidenib — Dr Halpern (55:23)